Literature DB >> 22324878

Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B?

Luz Martín-Carbonero1, Norma I Rallón, José M Benito, Eva Poveda, Juan González-Lahoz, Vincent Soriano.   

Abstract

Single nucleotide polymorphisms (SNP) nearby the IL28B gene have been associated with spontaneous hepatitis C virus (HCV) clearance and response to interferon-based therapies in both monoinfected and HIV-coinfected patients. However, its impact on spontaneous clearance of HBV (the pathogenesis of which is also related to interferon) is less known. A case-control study was performed. Cases were 49 HIV(+) patients with chronic hepatitis B (HBsAg(+) for more than 6 months) who had been genotyped for the rs12979860 SNP (protective CC genotype). One control for each case was chosen among HIV patients with anti-HBs and anti-HBc. Controls were matched for gender and coinfection with HCV. Most patients were male (90%) and the median (IQR) age was 42.6 (39-46.7) years. Eighteen (36.7%) were also coinfected by HCV. Among HBsAg(+) patients, 19 (41.3%) were HBeAg(+) and 13 (26.5%) were also infected with hepatitis delta (HDV). No differences were found in the distribution of the CC genotype between patients with chronic hepatitis B and those who spontaneously cured hepatitis B: 59.2% vs. 44.9%; p=0.3. Thus, the interleukin-28B (IL-28B) genotype does not seem to have a role in the development of chronic hepatitis B among HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22324878     DOI: 10.1089/AID.2011.0365

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

Review 1.  Interleukin 28B genetic polymorphism and hepatitis B virus infection.

Authors:  Toru Takahashi
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 2.  Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection.

Authors:  Semra Tunçbilek
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis.

Authors:  Pu Xia; Mo Zhou; Dao Song Dong; Ya-Nan Xing; Yang Bai
Journal:  Tumour Biol       Date:  2013-09-12

4.  Associations of IFN-γ rs2430561 T/A, IL28B rs12979860 C/T and ERα rs2077647 T/C polymorphisms with outcomes of hepatitis B virus infection: a meta-analysis.

Authors:  Shaidi Tang; Ming Yue; Jiajia Wang; Yun Zhang; Rongbin Yu; Jing Su; Zhihang Peng; Jie Wang
Journal:  J Biomed Res       Date:  2014-07-10

5.  Association between genetic polymorphisms of the IL28B gene and leukomonocyte in Chinese hepatitis B virus-infected individuals.

Authors:  Yuzhu Song; Yunsong Shen; Xueshan Xia; A-Mei Zhang
Journal:  PeerJ       Date:  2017-12-19       Impact factor: 2.984

6.  Association between IL28B Polymorphisms and Outcomes of Hepatitis B Virus Infection: A meta-analysis.

Authors:  Jingyu Zhao; Xinyue Zhang; Liwei Fang; Hong Pan; Jun Shi
Journal:  BMC Med Genet       Date:  2020-05-01       Impact factor: 2.103

7.  Absence of correlation between IL-28B gene polymorphisms and the clinical presentation of chronic hepatitis B in an Amazon Brazilian population.

Authors:  Simone Regina Souza da Silva Conde; Luciana L Rocha; Vanessa M Ferreira; Julius Caesar Mendes Soares Monteiro; Nathália Karla Fonseca Filgueiras; Pedro Alves de Almeida Lins; Bruna Tereza Silva dos Santos; Felipe Bonfim Freitas; Ednelza da Silva Graça; Sâmia Demachki; Marialva Tereza Ferreira de Araújo; Ricardo Ishak; Antonio C R Vallinoto
Journal:  Dis Markers       Date:  2014-04-10       Impact factor: 3.434

8.  The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection.

Authors:  Zahra Heidari; Bita Moudi; Hamidreza Mahmoudzadeh-Sagheb; Mohammad Hashemi
Journal:  Hepat Mon       Date:  2016-03-05       Impact factor: 0.660

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.